Physician profile
David Alexander
NPI 1619397890
$6,277.11
in general payments reported to CMS, 2019-2025
17 companies · $96.79 in 2025
The $96.79 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,127 · 2020: $460 · 2021: $737 · 2022: $822 · 2023: $1,146 · 2024: $888 · 2025: $96.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Travel and Lodging: $432 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.64 |
| Travel and Lodging | $432.30 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,021.27 | 2019-2025 | Audion Et Dilation System, Medpor, Medpor Contain |
| Inspire Medical Systems, INC. | $980.58 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $630.69 | 2021-2024 | Dupixent |
| Intersect Ent, INC. | $256.40 | 2019 | |
| Smith+Nephew, INC. | $243.33 | 2019-2022 | |
| Osiris Therapeutics INC. | $211.33 | 2019 | |
| Genzyme Corporation | $206.69 | 2019-2023 | |
| Glaxosmithkline, LLC. | $197.89 | 2021-2024 | Nucala |
| Biotissue Holdings INC. | $145.71 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $111.93 | 2019 | |
| Novo Nordisk INC | $109.14 | 2019 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Optinose US, INC. | $42.93 | 2019-2021 | |
| Kaleo, INC. | $18.44 | 2022 | |
| Alk-Abello, INC | $15.95 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.10 | 2023 | |
| Integra Lifesciences Corporation | $14.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.